for bowel and liver diseases
Our pharmaceuticals are used successfully to treat inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing prior to colonoscopies.
We focus on modern formulations and specially designed delivery systems to ensure targeted release of the active drug.
in the interest of therapeutic progress
Since 1967 we have arranged internationally recognized scientific congresses, the Falk Symposia and Workshops. So far more than 200 events have been attended by some 100,000 participants from over 100 countries.
We organize and sponsor continuing medical education events - to date over 13,000 seminars have been attended by over one million physicians and patients in Germany alone.
With more than 200 publications, which are updated regularly, we provide a comprehensive literature service for healthcare professionals as well as patients and their families.
Klinische Studie zur Beurteilung eines neuen, sich in der Erprobung befindlichen biologischen Medikaments. Der Name der Studie ist TRUST-2, was für „TRichUris Suis ova Trial“ steht.
Mehr als 200 Patienten mit MORBUS CROHN haben das sich in der Erprobung befindende Studienmedikament bisher in klinischen Studien eingenommen.
Die Studien zeigen eine Abnahme der Krankheitsaktivität und in der Mehrzahl der Fälle wurde Remission (beschwerdefreie Phase) erzielt. Die bisher beobachteten Nebenwirkungen betrafen zumeist den Verdauungstrakt.
